Neuberger Discusses Court Order Requiring Website to Identify Anonymous Reviewers
10 November 2017
Of Counsel Mark Neuberger is quoted in a Society for Human Resource Management article, “Court Orders Glassdoor to Reveal Reviewers’ Identities,” about the implications of an appeals court order requiring Glassdoor, a website where people can anonymously post reviews of workplaces, to comply with a subpoena seeking the identities of eight anonymous reviewers in connection with a grand jury investigation into possible fraud by a federal contractor.
Neuberger said the ruling should have little or no effect on the average contributor to websites such as Glassdoor. “This subpoena is not and should not be the end of sites like Glassdoor or other ones where people can comment about their doctors, restaurants or anything else,” he said.
Neuberger said the ruling should have little or no effect on the average contributor to websites such as Glassdoor. “This subpoena is not and should not be the end of sites like Glassdoor or other ones where people can comment about their doctors, restaurants or anything else,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”